5 Key Takeaways

• 1

  The FDA issued a Complete Response Letter for cytisinicline, citing manufacturing issues at a third-party facility and incomplete product labeling.

• 2

  No deficiencies related to the clinical efficacy or safety of cytisinicline were identified by the FDA.

• 3

  Achieve Life Sciences plans to resubmit the New Drug Application in the fourth quarter of 2026, reflecting a new manufacturing partnership.

• 4

  Cytisinicline has shown greater smoking abstinence rates in Phase 3 trials compared to placebo, with significant safety data from over 400 participants.

• 5

  Achieve Life Sciences is developing cytisinicline for smoking cessation and has received FDA Breakthrough Therapy designation for e-cigarette cessation.